Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center

To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Hematology (Luxembourg) Ročník 29; číslo 1; s. 2431958
Hlavní autoři:	Xu, Shuiqing, Chen, Wenming, Li, Yanchen
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis Group 01.12.2024
Témata:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use daratumumab-based daratumumab-free Female Humans Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality newly-diagnosed paraskeletal plasmacytomas Plasmacytoma - diagnosis Plasmacytoma - drug therapy Plasmacytoma - mortality Retrospective Studies risk factors risk factors Multiple myeloma overall survival daratumumab-free newly-diagnosed daratumumab-based paraskeletal plasmacytomas efficacy
ISSN:	1607-8454, 1607-8454
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!